Axonyx's Posiphen well tolerated during phase 1 trial in Alzheimer's patients

By Angela McDaniels

Seattle, Jan. 24 - Axonyx Inc. said it has completed the ascending single-dose phase 1 trial of Posiphen, in clinical development for the treatment of Alzheimer's disease progression.

The double-blind, placebo-controlled study of Posiphen in healthy volunteers sought to establish well-tolerated doses. Posiphen appears to be well tolerated at single doses up to and including 80 mg. No serious adverse events were reported at any dose level, the company said.

A major pathological hallmark of Alzheimer's disease is the appearance of senile plaques that are composed primarily of beta-amyloid derived from the protein beta-APP. Axonyx said Posiphen appears to modify the metabolism of beta-APP.

The company expects to begin a phase 1 ascending multiple-dose study soon.

Axonyx is a New York-based biopharmaceutical company that acquires and develops proprietary pharmaceutical compounds for the treatment of central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.